Overview
HUMA market data
Price History
HUMA price chart
Valuation & Profitability
No Valuation Data Yet
Alpha Vantage and Twelve Data both returned no valuation metrics for HUMA. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.
Company news
Humacyte Appoints Key Nephrologists as Advisors to Prepare for Planned Commercialization of the ATEV in Dialysis AccessGlobenewswire Inc · Jul 14, 2026, 12:15 PM
TD Cowen Maintains Buy on Humacyte, Lowers Price Target to $1.25Benzinga · Jun 17, 2026, 2:05 PM
Humacyte Reports Results From Its V012 Phase 3 Trial Of Bioengineered Blood Vessel At Society For Vascular Surgery's Vascular Annual MeetingBenzinga · Jun 15, 2026, 12:15 PM
HC Wainwright & Co. Maintains Buy on Humacyte, Raises Price Target to $4Benzinga · Jun 11, 2026, 3:43 PM
Why Is Humacyte Stock Falling Thursday?Benzinga · Jun 11, 2026, 3:21 PM
Reported Earlier, Humacyte Prices Public Offering Of 47,619,048 Common Shares At $1.05 Per Share Raising $50M To Fund Symvess Commercialization And Pipeline DevelopmentBenzinga · Jun 11, 2026, 7:19 AM
Humacyte Commences Common Stock Offering; Terms Not DisclosedBenzinga · Jun 10, 2026, 8:10 PM
Humacyte Announces Positive Interim Results From Phase Study Of Acellular Tissue Engineered Vessel In Female Patients For Dialysis Access, To Present Results June 11Benzinga · Jun 10, 2026, 8:10 PM
Benchmark Maintains Speculative Buy on Humacyte, Raises Price Target to $2Benzinga · Jun 1, 2026, 12:10 PM
HC Wainwright & Co. Reiterates Buy on Humacyte, Maintains $3 Price TargetBenzinga · May 26, 2026, 4:19 PM